LGT Fund Management Co Ltd. Buys Shares of 33,600 Halozyme Therapeutics, Inc. $HALO

LGT Fund Management Co Ltd. bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 33,600 shares of the biopharmaceutical company’s stock, valued at approximately $1,748,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HALO. Isthmus Partners LLC increased its position in Halozyme Therapeutics by 2.5% in the 1st quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock valued at $439,000 after acquiring an additional 169 shares during the period. OneDigital Investment Advisors LLC raised its stake in Halozyme Therapeutics by 1.7% during the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock valued at $649,000 after acquiring an additional 175 shares in the last quarter. Park Place Capital Corp raised its stake in Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after acquiring an additional 182 shares in the last quarter. Xponance Inc. raised its stake in Halozyme Therapeutics by 1.1% during the 1st quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock valued at $1,190,000 after acquiring an additional 198 shares in the last quarter. Finally, Bessemer Group Inc. raised its stake in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 207 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the transaction, the director directly owned 46,952 shares of the company’s stock, valued at approximately $3,459,423.36. The trade was a 7.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at $55,285,726.65. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 128,227 shares of company stock valued at $8,908,195. Corporate insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HALO. JMP Securities lifted their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research note on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Halozyme Therapeutics in a report on Saturday, September 27th. JPMorgan Chase & Co. increased their price objective on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $85.00 to $90.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $70.44.

Halozyme Therapeutics Stock Down 3.8%

HALO stock opened at $68.98 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $79.50. The company’s 50 day simple moving average is $70.45 and its 200-day simple moving average is $61.95. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The firm has a market capitalization of $8.07 billion, a P/E ratio of 15.78, a P/E/G ratio of 0.38 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. During the same quarter in the previous year, the business earned $0.91 earnings per share. The firm’s revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.